Hospira Inc: (NYSE: HSP)
$35.74
0.02 (0.06%)
Volume 1,300,278
May 17 04:01 PM ET
Zacks Rank: 3-Hold 
| #3 |
Overview Quote
Stock Activity
| Day Low - High | 35.45 - 36.20 |
| 52wk Low - High | 28.62 - 37.78 |
| Previous Close | 35.72 |
| Avg. Volume | 1,464,988 |
| Industry | MED PRODUCTS |
| Market Cap | 5.91 B |
| Div - Yield | 0.00 - 0.00 |
| Beta | 0.87 |
| PE (Forward) | 17.68 |
| Current Year Est. | 2.02 |
| Quarterly Earnings ESP |
0.00% |
Premium research
Zacks Rank
|
 3 |
Zacks Recommendation
|
Underperform |
Zacks Industry Rank
|
175 out of 265 |
Equity Research Report
|
PREMIUM |
( = Change in last 30 days)
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial
Key Earnings Data
| PE (Forward) | 17.68 |
| PEG Ratio | 2.40 |
| Current Year Est. | 2.02 |
| Current Quarter Estimate | 0.51 |
| Most Accurate Estimate | 0.51 |
| Earnings ESP |
0.00% |
| Next Earnings Report Date | 08-07-2013 |
| EPS Last Year | 2.05 |
| Expected Earnings Growth | 7.38% |
Company Description
Hospira Inc is a global specialty pharmaceutical and medication delivery company dedicated to Advancing Wellness by developing, manufacturing and marketing products that help improve the safety and efficacy of patient care. Their portfolio includes one of the industry's broadest lines of generic acute-care injectables, integrated solutions for medication management and infusion therapy, and a full-service contract manufacturing business.
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.
Turn Earnings Surprises into quick profits.
Earnings Estimates
| Current Qtr (06/2013) |
Next Qtr (09/2013) |
Current Year (12/2013) |
Next Year (12/2014) |
|
|---|---|---|---|---|
| Average Estimate | 0.51 | 0.44 | 2.02 | 1.98 |
| Number of Estimates | 9 | 8 | 9 | 9 |
| Low Estimate | 0.49 | 0.42 | 1.98 | 1.37 |
| High Estimate | 0.54 | 0.47 | 2.05 | NA |
| Year Ago EPS | 0.51 | 0.47 | 2.01 | 2.02 |
| EPS Growth | 0.44% | -5.59% | 0.55% | -2.03% |
Industry Analysis
| Name | Symbol | Previous Close | Zacks Rank | Zacks Recommendation |
|---|---|---|---|---|
| HOSPIRA INC | HSP | 35.74 | |
|
| CONCEPTUS INC | CPTS | 30.92 | |
|
| ATRICURE INC | ATRC | 9.07 | |
|
| CYTOSORBENTS CP | CTSO | 0.12 | |
|
| INVIVO THERAPT | NVIV | 2.89 | |
|
| TRANS1 INC | TSON | 1.70 | |
|
| ABAXIS INC | ABAX | 45.35 | |
|
| ADVAXIS INC | ADXS | 0.05 | |
|
| ALERE INC | ALR | 26.30 | |
|
| BAXTER INTL | BAX | 72.94 | |
|
Sector:Medical>> Industry:MED PRODUCTS
COMPARE TICKER vs. Its Peers
Zacks Commentary
Earnings Beat at Hospira
May 01, 2013
Zacks Bull and Bear of the Day Highlights: Safeway, Hospira, Montpelier Re Holdings, CNO Financial Group and Progressive
Mar 25, 2013
Bear of the Day: Hospira (HSP)
Mar, 25 2013 00:00
Pediatric Exclusivity for Hospira's Drug
Mar 19, 2013
Bearish MACD for Hospira, Inc.
Mar 05, 2013
Blow for HSP, 2013 View Withdrawn
Feb 19, 2013
Hospira Beats by a Penny
Feb 14, 2013
Hospira Inks Deal
Jan 24, 2013
Financials
| EPS TTM | 2.05 |
| Sales | 4,092 |
| Net Income | -73 |
| Price/Earnings | 17.43 |
| Price/Book | 1.98 |
| Price/Cash Flow | 10.17 |
| Price/Sales | 1.47 |
News
Summary of Jana Partners 13F: Aetna, Expedia and Kinder Morgan All Raised Among Others - Benzinga
May 15, 2013
Synta Is Run-Up to ASCO Lung Cancer Data - TheStreet.com
May 14, 2013
Synta Is a Run-Up Trade Into ASCO Lung Cancer Data - TheStreet.com
May 14, 2013
What to Expect from Hospira - TheMotleyFool
Apr 29, 2013
Brian Rogers of T Rowe Price Buys 4 New Stocks, Including Apple in Q1 - GuruFocus
Apr 17, 2013
Top 4 Stocks In The Drug Delivery Industry With The Highest Profit Margin - Benzinga
Apr 10, 2013
Investor???s Dilemma - TheMotleyFool
Apr 1, 2013
Will Hospira Get Hit With FDA Consent Decree Over Factory Lapses? - YCharts
Apr 1, 2013
Broker Recommendations
| Current ABR | 3.33 |
| ABR (Last Week) | 3.33 |
| # of recs in ABR | 12 |
| Average Target Price | 31.36 |
| Industry Rank by ABR | 175 out of 265 |
| Rank in Industry | 6 out of 72 |
